Diagnostic value of <scp>STMN</scp>1, <scp>LMO</scp>2, <scp>HGAL</scp>,<scp> AID</scp> expression and 1p36 chromosomal abnormalities in primary cutaneous B cell lymphomas

Verdanet, Evelyne; Dereure, O.; René, Céline; Tempier, Ariane; Benammar-Hafidi, Assia; Gallo, Mathieu; Frouin, Éric; Durand, L; Gazagne, I.; Costes-Martineau, Valérie; Cacheux, Valère; Szablewski, Vanessa

doi:10.1111/his.13279

Cited by 20 publications

(13 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…6,8 The neoplastic lymphocytes in PCFCL express B-cell markers (CD19, CD20, CD22, CD79a, PAX5) and at least one follicle center marker, which is usually BCL6 or, less commonly, CD10 ( Figure 2, D and E). 2,3,12,13,17,20 BCL2 staining is usually absent. 4,12,13,17,18 Ki-67 may reveal a lower proliferation index than usual in reactive follicles and will not show the customary polarization of a reactive follicle.…”

Section: Epidemiology and Clinical Featuresmentioning

confidence: 99%

“…3,13,15,17,18 Similarly, 1p36 deletion and rearrangements of BCL6 are more common in FL but are rarely detected in PCFCL. 18,20 Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type…”

Section: Differential Diagnosismentioning

confidence: 99%

“…37 Primary cutaneous marginal zone lymphomas lack expression of BCL6, CD10, and CD5 but may express CD43, unlike PCFCL. In addition, PCMZL lacks the germinal center marker STMN1 (stathmin), which is expressed by PCFCL and PCDLBCL-LT. 18,20 In addition, PCMZLs often include light-chain-restricted plasma cells, which are not usually seen in PCFCL. rare and relatively recently described lymphoma with only few reported cases, 38,39 and it is not included in the current World Health Organization classification system.…”

Section: Primary Cutaneous Marginal Zone Lymphomamentioning

confidence: 99%

See 2 more Smart Citations

Primary Cutaneous Follicle Center Lymphoma

Skala¹,

Hristov²,

Hristov

2018

Archives of Pathology &Amp; Laboratory Medicine

View full text Add to dashboard Cite

Context.— Primary cutaneous follicle center lymphoma is a low-grade B-cell lymphoma that is limited to the skin at diagnosis. It has a differential diagnosis that includes systemic/nodal follicular lymphoma secondarily involving the skin; primary cutaneous diffuse large B-cell lymphoma leg type; reactive lymphoid hyperplasia; and primary cutaneous marginal zone lymphoma. Objective.— To review the clinical, morphologic, immunophenotypic, and genetic features of primary cutaneous follicle center lymphoma; its differential diagnosis; and the evidence that supports use of immunohistochemistry and genetic testing in the diagnosis and prognosis of this entity. Data Sources.— Pertinent literature regarding cutaneous B-cell lymphomas is summarized and University of Michigan cases are used to highlight characteristics of primary cutaneous follicle center lymphoma. Conclusions.— Primary cutaneous follicle center lymphoma is a low-grade B-cell lymphoma with distinctive features, although some cases may have elements that overlap with other lymphomas, complicating interpretation.

show abstract

Section: Epidemiology and Clinical Featuresmentioning

confidence: 99%

“…3,13,15,17,18 Similarly, 1p36 deletion and rearrangements of BCL6 are more common in FL but are rarely detected in PCFCL. 18,20 Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type…”

Section: Differential Diagnosismentioning

confidence: 99%

Section: Primary Cutaneous Marginal Zone Lymphomamentioning

confidence: 99%

See 1 more Smart Citation

Primary Cutaneous Follicle Center Lymphoma

Skala¹,

Hristov²,

Hristov

2018

Archives of Pathology &Amp; Laboratory Medicine

View full text Add to dashboard Cite

show abstract

“…Its expression was detected in FL, especially when germinal center markers such as CD10 and/or Bcl-6 were negative [ 18 ]. It was reported as being very helpful in the distinction between FL and MZLs in skin [ 19 ].…”

Section: Introductionmentioning

confidence: 99%

Relevance of Additional Immunohistochemical Markers in the Differential Diagnosis of Small B-Cell Lymphomas: A Case-Control Study

Kıvrak¹,

Yüksel²,

Ateş³

et al. 2022

Tjh

View full text Add to dashboard Cite

Objective: Clinical and pathological differential diagnosis of small B-cell lymphomas (SBCLs) is still controversial and may be difficult due to their overlapping morphology, phenotype, and differentiation to plasma cells. We aimed to examine the expression of the immune receptor translocation-associated protein 1 (IRTA1), myeloid cell nuclear differentiation antigen (MNDA), lymphoid enhancer-binding factor-1 (LEF1), and stathmin 1 (STMN1) markers in SBCL cases involving different sites that may have plasma cell differentiation. Materials and Methods: We studied 154 tissue samples with lymphoma involvement from 116 patients and evaluated the staining distribution of the markers. Expressions were evaluated in 21 chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), 7 follicular lymphoma (FL), 14 nodal marginal zone lymphoma, 17 extranodal marginal zone lymphoma, 55 splenic marginal zone lymphoma, 22 marginal zone lymphoma-not otherwise specified, and 18 lymphoplasmacytic lymphoma/Waldenström macroglobulinemia cases by immunohistochemistry. Results: The results confirmed that LEF1 was the most sensitive and specific marker for CLL/SLL and STMN1 was the most sensitive and specific marker for FL (p<0.001). MNDA and IRTA1 were useful markers to distinguish marginal zone lymphomas. Conclusion: Our results suggest that LEF1 for CLL/SLL and STMN1 for FL are reliable markers. LEF1, MNDA, STMN1, and IRTA1 are helpful with other routinely used immunohistochemical markers in a diagnostic algorithm considering their limitations.

show abstract

“…Plasma cells are more often polyclonal by testing Immunoglobulin (Ig) light chain immunostains. Myeloid cell nuclear differentiation antigen (MNDA) has recently emerged as a useful marker in MZL, but its diagnostic 40 Primary cutaneous plasmacytoid dendritic cells have been hypothesised to have a diagnostic role, as large clusters have been observed in PC-MZL rather than in reactive B-cell infiltrates. 41 Actually, two groups of PC-MZL are defined on the basis of the expression of surface immunoglobulins: the "class-switched" group expresses IgG or, more rarely, IgA and IgE, and is characterized by a nodular and scattered distribution of B-cells, and many T-cells, mainly Th2.…”

Section: Pathological Findingsmentioning

confidence: 99%

Dermatological Considerations in the Diagnosis and Treatment of Marginal Zone Lymphomas

Ronchi

Sica

Vitiello

et al. 2021

CCID

View full text Add to dashboard Cite

Primary cutaneous marginal zone lymphoma (PC-MZL) is a B-cell lymphoma arising in the skin. Although it is a rare disease, PC-MZL accounts for 20–40% of all primary cutaneous B-cell lymphoma in Western Countries. The aetiology and the pathogenesis of PC-MZL are poorly understood, as it generally lacks the chromosomal translocations most typically present in marginal zone lymphomas of other sites. The diagnosis of PC-MZL may be challenging, due to the rarity of the disease, and needs the competence of different professional figures, including the dermatologist and the pathologist. Furthermore, the management of the patient after the diagnosis is complex and involves the dermatologist, the haematologist, the surgeon, the radiotherapist and the radiologist. The aim of this review is to describe the clinical and histological findings for the diagnosis of PC-MZL, and the state of art for the management of the patient.

show abstract

Diagnostic value of STMN1, LMO2, HGAL, AID expression and 1p36 chromosomal abnormalities in primary cutaneous B cell lymphomas

Abstract: LMO2, HGAL, STMN1 and AID, but not MNDA, are discriminant for the recognition between CFL and CMZL. BCL2, BCL6 rearrangements and the del 1p36 have a role in the pathogenesis of PCFL, the latest being the most common alteration.

Cited by 20 publications

References 29 publications

Primary Cutaneous Follicle Center Lymphoma

Primary Cutaneous Follicle Center Lymphoma

Relevance of Additional Immunohistochemical Markers in the Differential Diagnosis of Small B-Cell Lymphomas: A Case-Control Study

Dermatological Considerations in the Diagnosis and Treatment of Marginal Zone Lymphomas

Contact Info

Product

Resources

About